Alpharadin, an injectable drug containing a radioactive isotope, is becoming a viable option for prostate cancer patients whose cancer has metastasized to the bone or those who no longer respond to other treatments. The drug, which is in final Phase III trials, can precisely target and treat metastatic cancer in bones to spare healthy cells. "Results have been very positive and have suggested it is increasing survival rates," said a doctor who is part of the study.

Related Summaries